東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Resistance of cancer cells to CTL-me...

Bonavida, Benjamin.

FindBook

Google Book

Amazon

博客來

Resistance of cancer cells to CTL-mediated immunotherapy

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Resistance of cancer cells to CTL-mediated immunotherapy/ edited by Benjamin Bonavida, Salem Chouaib.
其他作者:	Bonavida, Benjamin.
出版者:	Cham :Springer International Publishing : : 2015.,
面頁冊數:	xiv, 353 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer eBooks
標題:	Drug resistance in cancer cells. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-17807-3
ISBN:	9783319178073 (electronic bk.)

Resistance of cancer cells to CTL-mediated immunotherapy
Resistance of cancer cells to CTL-mediated immunotherapy[electronic resource] /edited by Benjamin Bonavida, Salem Chouaib. - Cham :Springer International Publishing :2015. - xiv, 353 p. :ill. (some col.), digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.72196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.4..

This book, written by leading investigators, brings together the latest knowledge about key aspects of the most rapidly progressing fields of tumor escape and tumor resistance to CTL. Readers will benefit from a collection of outstanding surveys that cover some factors regulating resistance to CTL cytotoxicity, the influence of tumor microenvironment, and the resistance to death ligands, mediated apoptosis, and means to reverse resistance. This remarkable volume also emphasizes the future directions that may lead to the design of more innovative, refined, and integrative immunotherapies to target tumor plasticity and heterogeneity, and help to overcome the inherent limitations of current treatments. By providing a broad scope of innovative concepts in the burgeoning field of cancer biology and immunotherapy, this volume will be of exceptional interest and a valuable reference for scientists, clinicians, health professionals, and biopharmaceutical companies working in the field of cancer immunotherapy.

ISBN: 9783319178073 (electronic bk.)

Standard No.: 10.1007/978-3-319-17807-3doiSubjects--Topical Terms:

658434
Drug resistance in cancer cells.

LC Class. No.: RC271.I45

Dewey Class. No.: 616.99406

Resistance of cancer cells to CTL-mediated immunotherapy
LDR:02063nam a2200313 a 4500 001 2007422
003 DE-He213
005 20160111144550.0
006 m d
007 cr nn 008maaau
008 160219s2015 gw s 0 eng d
020 $a 9783319178073 (electronic bk.)
020 $a 9783319178066 (paper)
024 7 $a 10.1007/978-3-319-17807-3 $2 doi
035 $a 978-3-319-17807-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.I45
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99406 $2 23
090 $a RC271.I45 $b R433 2015
245 0 0 $a Resistance of cancer cells to CTL-mediated immunotherapy $h [electronic resource] / $c edited by Benjamin Bonavida, Salem Chouaib.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a xiv, 353 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Resistance to targeted anti-cancer therapeutics, $x 2196-5501 ; $v v.7
520 $a This book, written by leading investigators, brings together the latest knowledge about key aspects of the most rapidly progressing fields of tumor escape and tumor resistance to CTL. Readers will benefit from a collection of outstanding surveys that cover some factors regulating resistance to CTL cytotoxicity, the influence of tumor microenvironment, and the resistance to death ligands, mediated apoptosis, and means to reverse resistance. This remarkable volume also emphasizes the future directions that may lead to the design of more innovative, refined, and integrative immunotherapies to target tumor plasticity and heterogeneity, and help to overcome the inherent limitations of current treatments. By providing a broad scope of innovative concepts in the burgeoning field of cancer biology and immunotherapy, this volume will be of exceptional interest and a valuable reference for scientists, clinicians, health professionals, and biopharmaceutical companies working in the field of cancer immunotherapy.
650 0 $a Drug resistance in cancer cells. $3 658434
650 0 $a Cancer $x Immunotherapy. $3 656051
650 1 4 $a Biomedicine. $3 890831
650 2 4 $a Cancer Research. $3 891172
650 2 4 $a Drug Resistance. $3 836316
650 2 4 $a Molecular Medicine. $3 890952
700 1 $a Bonavida, Benjamin. $3 907967
700 1 $a Chouaib, Salem. $3 2156194
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Resistance to targeted anti-cancer therapeutics ; $v v.4. $3 2130880
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-17807-3
950 $a Biomedical and Life Sciences (Springer-11642)